Biểu đồ giá cổ phiếu CABA
CABA Dự đoán giá cổ phiếu
Cabaletta Bio Inc
$3.83
30.27%
$0.89
Khi đóng cửa: May 04, 16:00:00 GMT-4
$3.85
0.53%
$0.02
Phiên trước giờ: May 05, 07:17:56 GMT-4
Quay lại
Cabaletta Bio Inc (CABA) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$2.94
Giá mở cửa
$3.18
Phạm vi ngày
$3.16 - $4.04
Phạm vi 52 tuần
$1.11 - $3.85
Khối lượng
29.1M
Khối lượng trung bình
2.6M
Tỷ suất cổ tức
--
EPS (TTM)
-2.28
Vốn hóa thị trường
$428.6M
CABA là gì?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
